Published in Blood on January 01, 2001
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell (2007) 4.21
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A (2006) 3.48
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol (2006) 2.28
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood (2012) 1.67
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood (2007) 1.61
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia (2009) 1.33
Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol (2014) 1.23
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood (2008) 1.17
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med (2012) 1.10
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol (2004) 1.02
IRF-4 functions as a tumor suppressor in early B-cell development. Blood (2008) 1.01
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood (2005) 0.94
A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica (2009) 0.94
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. PLoS One (2009) 0.91
Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer (2012) 0.90
Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med (2012) 0.86
The Philadelphia chromosome in leukemogenesis. Chin J Cancer (2016) 0.86
IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood (2014) 0.85
Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia. Genes Dev (2016) 0.81
Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood (2016) 0.80
Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease. Proc Natl Acad Sci U S A (2008) 0.79
BCR/ABL can promote CD19(+) cell growth but not render them long-term stemness. Stem Cell Investig (2016) 0.75
The calcineurin protein phosphatase is dispensable for BCR-ABL-induced B-ALL maintenance, propagation and response to dasatinib. Leukemia (2016) 0.75
Sequence and gene organization of mouse mitochondrial DNA. Cell (1981) 13.14
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
Precise localization and nucleotide sequence of the two mouse mitochondrial rRNA genes and three immediately adjacent novel tRNA genes. Cell (1980) 4.41
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med (1999) 4.06
Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet (2000) 3.67
Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron (2000) 2.82
Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol Cell Biol (1992) 2.60
P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem (1996) 2.47
Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. Science (1988) 2.29
Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem (1995) 2.20
c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem (2000) 2.17
v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc Natl Acad Sci U S A (1991) 1.86
Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest (1996) 1.82
Isolation of mammalian mitochondrial DNA and RNA and cloning of the mitochondrial genome. Methods Enzymol (1983) 1.76
The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev (1997) 1.72
The CD11b promoter directs high-level expression of reporter genes in macrophages in transgenic mice. Blood (1995) 1.61
The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J (1996) 1.60
Phosphatidylinositol 3-kinase and its novel product, phosphatidylinositol 3-phosphate, are present in Saccharomyces cerevisiae. J Biol Chem (1989) 1.53
Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. EMBO J (2001) 1.52
Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein. J Cell Biol (2000) 1.45
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res (1993) 1.43
Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood (1999) 1.42
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood (2001) 1.41
Role of PI 3-kinase in angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells. Exp Cell Res (1999) 1.36
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer (2008) 1.27
Association of phosphatidylinositol 3-kinase with a specific sequence of the T cell receptor zeta chain is dependent on T cell activation. J Biol Chem (1994) 1.27
Interleukin-2 receptor regulates activation of phosphatidylinositol 3-kinase. J Biol Chem (1991) 1.26
Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer (2010) 1.23
Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J Clin Invest (2000) 1.21
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood (2000) 1.20
Platelet-derived growth factor activates membrane-associated phosphatidylinositol 3-kinase and mediates its translocation from the cytosol. Detection of enzyme activity in detergent-solubilized cell extracts. J Biol Chem (1992) 1.18
The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood (1995) 1.15
Identification of the 3'-ends of the two mouse mitochondrial ribosomal RNAs. The 3'-end of 16 S ribosomal RNA contains nucleotides encoded by the gene for transfer RNALeuUUR. J Biol Chem (1983) 1.10
Divergence in signal transduction pathways of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors. Involvement of sphingosine 1-phosphate in PDGF but not EGF signaling. J Biol Chem (1997) 1.10
Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol Cell Biol (1992) 1.08
Studies on fenestral contraction in rat liver endothelial cells in culture. Am J Pathol (1996) 1.07
BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia (1996) 1.02
The role of phosphoinositide 3-kinase in taurocholate-induced trafficking of ATP-dependent canalicular transporters in rat liver. J Biol Chem (1998) 1.00
Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene (2001) 1.00
Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci U S A (1991) 0.99
Phosphoinositide 3-kinase lipid products regulate ATP-dependent transport by sister of P-glycoprotein and multidrug resistance associated protein 2 in bile canalicular membrane vesicles. Proc Natl Acad Sci U S A (1999) 0.97
Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene (2000) 0.96
Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells. Oncogene (1995) 0.96
Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells. Hepatology (1999) 0.94
PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood (1996) 0.93
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia (2008) 0.93
Tyrosine phosphorylation of the CD3-epsilon subunit of the T cell antigen receptor mediates enhanced association with phosphatidylinositol 3-kinase in Jurkat T cells. J Biol Chem (1997) 0.90
Biosynthesis of porphyrin precursors. Purification and characterization of mammalian L-alanine:gamma,delta-dioxovaleric acid aminotransferase. J Biol Chem (1980) 0.90
Probing fibroblast growth factor dimerization and role of heparin-like glycosaminoglycans in modulating dimerization and signaling. J Biol Chem (2001) 0.89
Serine-rich region of the IL-2 receptor beta-chain is required for activation of phosphatidylinositol 3-kinase. Cell Immunol (1994) 0.89
Paradoxical stimulation of both lipocortin and prostaglandin production in human amnion cells by dexamethasone. Biochem Biophys Res Commun (1988) 0.86
Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase. Oncogene (1997) 0.86
Biosynthesis of porphyrin precursors: kinetic studies on mammalian L-alanine: gamma,delta-dioxovaleric acid aminotransferase. Int J Biochem (1980) 0.83
Childhood leukemia: electric and magnetic fields as possible risk factors. Environ Health Perspect (2003) 0.83
Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization. J Biol Chem (2001) 0.83
Evidence for phosphatidylinositol 3-kinase-dependent T cell antigen receptor (TCR) signal transduction. Mol Immunol (1997) 0.82
Phorbol ester treatment inhibits phosphatidylinositol 3-kinase activation by, and association with, CD28, a T-lymphocyte surface receptor. Proc Natl Acad Sci U S A (1995) 0.81
Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. Proc Natl Acad Sci U S A (1995) 0.80
Dynamin inhibits phosphatidylinositol 3-kinase in hematopoietic cells. Biochim Biophys Acta (2001) 0.79
Bupropion in depression: a tri-center placebo-controlled study. J Clin Psychiatry (1983) 0.77
Phosphatidylinositol 3-kinase activity in murine erythroleukemia cells during DMSO-induced differentiation. Exp Cell Res (1995) 0.77
Expression of tie1 and tie2 proteins during reendothelialization in balloon-injured rat carotid artery. J Vasc Res (1999) 0.76
Naturally occurring ether-linked phosphatidylcholine activates phosphatidylinositol 3-kinase and stimulates cell growth. J Cell Biochem (1994) 0.76
Inactivation of wild-type BCR/ABL tyrosine kinase in hematopoietic cells by mild hyperthermia. Leukemia (2000) 0.76
c-fos is not essential for v-abl-induced lymphomagenesis. Cancer Res (1995) 0.75
The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein. Blood (1998) 0.75
Anti-platelet and anti-DNA IgM in Waldenström macroglobulinemia and ITP. Am J Hematol (1987) 0.75
Effect of a xanthine analog on human hepatocellular carcinoma cells (Alexander) in culture and in xenografts in SCID mice. Hepatology (1997) 0.75
Signal transduction and phosphoinositide metabolism in liver. Prog Liver Dis (1990) 0.75
Mitogenic signaling by cyclic adenosine monophosphate in chromaffin cells involves phosphatidylinositol 3-kinase activation. J Cell Biochem Suppl (2001) 0.75
Malignant transformation by abl and BCR/ABL. Cancer Treat Res (1992) 0.75